← All news
Markets
Celldex Therapeutics, Inc. (CLDX) Discusses Positive Phase 3 Results for Barzolvolimab in Chronic Spontaneous Urticaria - Slideshow
Covered by 1 outlet
All coverage · 2 articles
Seeking Alpha
·Sep 22, 19:19 UTC
Celldex Therapeutics, Inc. (CLDX) Discusses Positive Phase 3 Results for Barzolvolimab in Chronic Spontaneous Urticaria Transcript
Seeking Alpha
·Sep 22, 19:00 UTC